These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 20626664)
21. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Saku K; Zhang B; Noda K; Circ J; 2011; 75(6):1493-505. PubMed ID: 21498906 [TBL] [Abstract][Full Text] [Related]
22. No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study. Panayiotou G; Paschalis V; Nikolaidis MG; Theodorou AA; Deli CK; Fotopoulou N; Fatouros IG; Koutedakis Y; Sampanis M; Jamurtas AZ Scand J Med Sci Sports; 2013 Oct; 23(5):556-67. PubMed ID: 22288788 [TBL] [Abstract][Full Text] [Related]
24. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial. Zhao SP; Yu BL; Peng DQ; Huo Y Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217 [TBL] [Abstract][Full Text] [Related]
25. The effect of statins on skeletal muscle function: the STOMP trial. Farmer JA Curr Atheroscler Rep; 2013 Aug; 15(8):347. PubMed ID: 23843151 [No Abstract] [Full Text] [Related]
26. Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study. Tani S; Nagao K; Hirayama A Am J Cardiovasc Drugs; 2012 Oct; 12(5):349-54. PubMed ID: 22900989 [TBL] [Abstract][Full Text] [Related]
27. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. Bone HG; Kiel DP; Lindsay RS; Lewiecki EM; Bolognese MA; Leary ET; Lowe W; McClung MR J Clin Endocrinol Metab; 2007 Dec; 92(12):4671-7. PubMed ID: 17726081 [TBL] [Abstract][Full Text] [Related]
28. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy. Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143 [TBL] [Abstract][Full Text] [Related]
29. Effect of two intensive statin regimens on progression of coronary disease. Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316 [TBL] [Abstract][Full Text] [Related]
30. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Glueck CJ; Abuchaibe C; Wang P Med Hypotheses; 2011 Oct; 77(4):658-61. PubMed ID: 21802861 [TBL] [Abstract][Full Text] [Related]
32. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
33. Mitochondria of trained skeletal muscle are protected from deleterious effects of statins. Bouitbir J; Daussin F; Charles AL; Rasseneur L; Dufour S; Richard R; Piquard F; Geny B; Zoll J Muscle Nerve; 2012 Sep; 46(3):367-73. PubMed ID: 22907227 [TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077 [TBL] [Abstract][Full Text] [Related]
35. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Malhotra HS; Goa KL Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468 [TBL] [Abstract][Full Text] [Related]
36. Persisting weakness after withdrawal of a statin. Mygland Å; Ljøstad U; Krossnes BK BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24713712 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA; JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291 [TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of atorvastatin in heart transplant recipients. Patel DN; Pagani FD; Koelling TM; Dyke DB; Baliga RR; Cody RJ; Lake KD; Aaronson KD J Heart Lung Transplant; 2002 Feb; 21(2):204-10. PubMed ID: 11834348 [TBL] [Abstract][Full Text] [Related]
39. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Malinowski JM Am J Health Syst Pharm; 1998 Nov; 55(21):2253-67; quiz 2302-3. PubMed ID: 9825877 [TBL] [Abstract][Full Text] [Related]
40. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. Cromwell WC; Ziajka PE Am J Cardiol; 2000 Nov; 86(10):1123-7. PubMed ID: 11074211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]